Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML1103

Sigma-Aldrich

Entecavir

≥98% (HPLC)

Sinonimo/i:

2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one, BMS 200475, SQ 34,676

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C12H15N5O3
Numero CAS:
142217-69-4
Peso molecolare:
277.28
Numero MDL:
MFCD11046562
Codice UNSPSC:
51111800
ID PubChem:
329825478
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Attività ottica

[α]/D +25 to +40°, c = 0.2 in H2O

Condizioni di stoccaggio

desiccated

Colore

white to beige

Solubilità

H2O: 0.5 mg/mL, clear (warmed)

Temperatura di conservazione

−20°C

Stringa SMILE

O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](CO)C3=C)C=N2)NC(N)=N1

InChI

1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1
QDGZDCVAUDNJFG-FXQIFTODSA-N

Azioni biochim/fisiol

Entecavir is an antiviral guanine analog that inhibits reverse transcription, DNA replication and transcription in the viral replication process. Entecavir is used to treat hepatitis B.
Entecavir is an antiviral guanine analog that inhibits reverse transcription, DNA replication and transcription.
Entecavir is used as an effective drug to treat lamivudine-refractory patients with chronic hepatitis B virus (CHB) at a dose of 1 mg daily.

Pittogrammi

Health hazardExclamation mark
GHS08,GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H351

Classi di pericolo

Acute Tox. 4 Oral - Carc. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
084M4716V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Adefovir ≥98% (HPLC)

Sigma-Aldrich

SML0240

Adefovir

Interferon Alpha 2A human recombinant, expressed in HEK 293 cells, ≥98% (SDS-PAGE), lyophilized powder

Sigma-Aldrich

SRE0013

Interferon Alpha 2A human

Darunavir ≥98% (HPLC)

Sigma-Aldrich

SML0937

Darunavir

Cyclosporin A 97.0-101.5% (on dried basis)

Sigma-Aldrich

30024

Cyclosporin A

Masashi Iwamoto et al.
Scientific reports, 7(1), 10620-10620 (2017-09-08)
Viruses exploit host factors and environment for their efficient replication. The virus-host interaction mechanisms for achieving an optimal hepatitis B virus (HBV) replication have been largely unknown. Here, a single cell cloning revealed that HepAD38 cells, a widely-used HBV-inducible cell
Mariko Suzuki et al.
Scientific reports, 7, 41851-41851 (2017-02-06)
The complicated replication mechanisms of hepatitis B virus (HBV) have impeded HBV studies and anti-HBV therapy development as well. Herein we report efficient genome replication of HBV applying adenovirus vectors (AdVs) showing high transduction efficiency. Even in primary hepatocytes derived
Amir Shlomai et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(33), 12193-12198 (2014-08-06)
Hepatitis B virus (HBV) chronically infects 400 million people worldwide and is a leading driver of end-stage liver disease and liver cancer. Research into the biology and treatment of HBV requires an in vitro cell-culture system that supports the infection
Philip Rosenthal et al.
Hepatology (Baltimore, Md.), 69(6), 2326-2337 (2018-10-16)
The optimal management strategy for children with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children
Li-Ting He et al.
World journal of gastroenterology, 22(46), 10210-10218 (2016-12-29)
To investigate the efficacy of switching to pegylated interferon-α-2a (PegIFNα-2a) treatment in nucleos(t)ide analog (NA)-treated chronic hepatitis B (CHB) responder patients. A 48-wk prospective and retrospective treatment trial of NA-treated CHB patients who had received entecavir (ETV) for at least
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.